Carregant...
Standardizing total kidney volume measurements for clinical trials of autosomal dominant polycystic kidney disease
BACKGROUND: The ability of unstandardized methods to track kidney growth in clinical trials for autosomal dominant polycystic kidney disease (ADPKD) has not been critically evaluated. METHODS: The Tolvaptan Efficacy and Safety Management of ADPKD and its Outcomes (TEMPO) 3:4 study involved baseline...
Guardat en:
| Publicat a: | Clin Kidney J |
|---|---|
| Autors principals: | , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Oxford University Press
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6366146/ https://ncbi.nlm.nih.gov/pubmed/30746130 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ckj/sfy078 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|